Acasti Pharma Inc ACST

Wow

[boozehound3]

Did you see the new seeking alpha article

[LifeGoesOn1973]

yeah, weak content, nothing in it convinced me. lots of IFs in it, seems like a shorter trying to create some panic

[LifeGoesOn1973]

like for example he talks about the GLucose not diminishing , just for info, the Glucose value measures the concentration of glucose in the bloodstream at the instant you pick your finger while the HBA1c measures your average blood sugar over the past 2-3 months. It's a way to gauge long-term glucose control, or lack of it. so for diabetic patients the real indication is HBA1C because the

[lscfa]

  Author is biased and clueless about how an outcomes study would be funded.   Disclosure: I am/we are long AMRN. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.  

[lscfa]

Twisting the truth? Seeking Alpha article: While an outcome trial will unlikely be needed for a hypertriglyceridemia label, subsequent uptake in the marketplace likely will. During the 2020 Q2 conference call, ACST management had indicated that the likelihood of an outcomes trial was high.   Jan D’Alvise Yes. Thanks, Leland. So let me respond and then Pierre you’re welcome to

[boozehound3]

yep she sure is!

[lscfa]

Scumbag author still trying to mislead.... AMReply0Like   lscfa   Comments65 | Following Co. actually said:  But I think that clearly we may ultimately need to conduct an outcome trial but we believe that if our Phase 3 results can replicate our Trifecta Effect as we saw in Phase 2, we

[Francine01]

Like LifeGoeson1973 said, who care!? In a few days, we will know who's right and who's wrong. for the topline, science seems to be on our side :)